Arvinas 過去の業績

過去基準チェック /06

Arvinasの収益は年間平均-30%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間1.2% 30.6%割合で増加しています。

主要情報

-30.0%

収益成長率

-19.7%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	30.6%
株主資本利益率	-52.7%
ネット・マージン	-191.6%
前回の決算情報	30 Sep 2024

Recent updates

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

収支内訳

Arvinas の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:ARVN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	161	-309	158	360
30 Jun 24	93	-323	105	359
31 Mar 24	71	-355	100	369
31 Dec 23	79	-367	100	380
30 Sep 23	159	-295	88	383
30 Jun 23	158	-298	86	374
31 Mar 23	137	-301	84	346
31 Dec 22	131	-282	80	315
30 Sep 22	127	-253	83	279
30 Jun 22	103	-233	79	242
31 Mar 22	75	-213	70	210
31 Dec 21	54	-191	62	180
30 Sep 21	23	-180	55	152
30 Jun 21	21	-164	48	141
31 Mar 21	21	-139	43	122
31 Dec 20	26	-119	38	108
30 Sep 20	24	-99	33	96
30 Jun 20	47	-86	32	82
31 Mar 20	45	-78	30	75
31 Dec 19	43	-70	27	67
30 Sep 19	42	-65	26	61
30 Jun 19	15	-173	22	58
31 Mar 19	14	-179	17	52
31 Dec 18	14	-240	13	45
30 Sep 18	13	-233	8	37
30 Jun 18	12	-114	5	31
31 Mar 18	10	-98	4	29
31 Dec 17	8	-29	4	29
31 Dec 16	7	-12	3	20

質の高い収益: ARVNは現在利益が出ていません。

利益率の向上: ARVNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ARVNは利益が出ておらず、過去 5 年間で損失は年間30%の割合で増加しています。

成長の加速: ARVNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ARVNは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 54.6% ) と比較することは困難です。

株主資本利益率

高いROE: ARVNは現在利益が出ていないため、自己資本利益率 ( -52.66% ) はマイナスです。

Arvinas 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus revenue estimates increase by 20%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

過去基準チェック /06